ACST Stock – (NASDAQ: ACST) is actually giving an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the use of its “at-the market” equity offering program.

As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti might issue and sell from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being marketed at prevailing market costs averaging US$1.0747 per share. No securities were marketed throughout the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will provide the Company with supplemental freedom in its continuous review process to explore and evaluate strategic options.

About Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescription drugs making use of OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety and efficacy for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for individuals with serious HTG.

Forward Looking Statements – ACST Stock

Statements in this press release that are not statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, as well as other unknown components that might cause the actual results of Acasti to be materially different from historical outcomes and from any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the particular date of this press release. Forward-looking statements in this press release include, but are not confined to, statements or information about Acasti’s strategy, future operations and the review of its of strategic alternatives.

The forward looking claims found in this press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor area of Acasti’s website at www.acastipharma.com. Many forward looking statements in this press release are manufactured as of the particular date of this particular press release.

ACST Stock – Acasti does not undertake to redesign any such forward-looking statements whether as a direct result of information which is brand new, future events or even otherwise, except as required by law. The forward looking assertions contained herein are also subject typically to assumptions and risks as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use